Developing stable cell lines is a complex, time-intensive process involving numerous steps.

The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies

Mitigating the aggregation challenge in immunocytokine production: Strategies during cell line development and purification optimization

Directed Evolution for Protein Engineering

Pharma Turns to New Tech for Biologics

Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters

Will we be protected from COVID-19’s omicron variant? Bay Area researchers sprint to find out

Fighting for Our Lives

Inom en timme hade vi tio rush-orders

Biotech firm rebounds to combat coronavirus

This Biotech Business Won\'t Let Cost Get in the Way of a Covid Cure

Debottlenecking Opportunities Clearer with a Bioprocessing 4.0 Perspective